Table 2.
Pharmacokinetics of GSK3052230: maximum concentration (Cmax) and time of maximum concentration (Tmax) at Day 1 of the indicated cycles of therapy
| Cycle 1 Day 1 | Cycle 2 Day 1 | Cycle 4 Day 1 | Cycle 6 Day 1 | |
|---|---|---|---|---|
| 10 mg/kg GSK3052230 + 500 mg/m2 Pemetrexed + 75 mg/m2 Cisplatin (N = 3) | ||||
| Cmax (ng/mL) | ||||
| n | 3 | 3 | 2 | 1 |
| Geometric mean | 170,235.8 | 174,512.6 | 228,905.3 | 189,264.6 |
| CVb% | 29 | 14 | 25 | NC |
| Tmax (h) | ||||
| Median (Min - Max) | 0.60 (0.5–0.6) | 0.50 (0.5–1.0) | 0.55 (0.5–0.6) | 1.10 |
| 15 mg/kg GSK3052230 + 500 mg/m2 Pemetrexed + 75 mg/m2 Cisplatin (N =25) | ||||
| Cmax (ng/mL) | ||||
| n | 9 | 7 | 5 | 2 |
| Geometric mean | 205,104.9 | 221,082.8 | 173,559.0 | 300,070.8 |
| CVb% | 24 | 19 | 99 | 12 |
| Tmax (h) | ||||
| Median (Min - Max) | 0.60 (0.4–1.5) | 0.40 (0.0–1.0) | 0.90 (0.4–1.0) | 0.65 (0.4–0.9) |
| 20 mg/kg GSK3052230 + 500 mg/m2 Pemetrexed + 75 mg/m2 Cisplatin (N =8) | ||||
| Cmax (ng/mL) | ||||
| n | 8 | 6 | 3 | 2 |
| Geometric mean | 230,098.6 | 150,590.0 | 386,342.2 | 340,679.9 |
| CVb% | 119 | 901 | 11 | 22 |
| Tmax (h) | ||||
| Median (Min - Max) | 0.65 (0.4–1.6) | 1.05 (0.4–2.3) | 0.50 (0.4–0.9) | 0.50 (0.5–0.5) |
CVb% = between-subject coefficient of variation; NC = not calculated